Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

  1. November 18, 2022

    Del. Court Says Pharma Co. Must Delist 'Orange Book' Patent

    Jazz Pharmaceuticals has two weeks to ask the U.S. Food and Drug Administration to pull a patent that purportedly covers a narcolepsy drug from the agency's so-called Orange Book after a Delaware federal court found that it covers a distribution method and not the drug itself.

  2. November 14, 2022

    FTC Says "Orange Book" Abuse Blocks Drug Competition

    The Federal Trade Commission urged a Delaware federal court to remove a patent for narcolepsy drug distribution from federal regulators' list of approved drugs and the patents covering them, arguing the patent was improperly included and is blocking competition.